Skip to main content
Home > Conferences > BioEquity Europe > Dates, Location & Schedules > Presenting Companies Schedule
BioCentury Conference Center

Bio€quity Europe 2016 Conference Agenda

Monday, May 9
19:00 - 21:00 Welcome Networking Reception at Scandic Copenhagen Hotel - Lounge Bar

Badge Pickup is open 18:30-21:00.

Vester Soegade 6
1601 Copenhagen, Denmark

Tuesday, May 10
07:45 Registration Opens and Light Breakfast (Conference Foyer)
09:00 - 09:30 Welcome and Official Greeting from the Organizers and Regional Hosts

Anna Chrisman, Group Managing Director, EBD Group
David Flores, Co-Founder, President & CEO, BioCentury
Dr. Søren Møller, Managing Partner, Novo Seeds
David Thomas, Director, Industry Research & Analysis, Biotechnology Innovation Organization (BIO)
09:30 - 10:30 Opening Plenary - The BioEquity Europe Face-Off - Lost in Translation

BioCentury is finding a fundamental disconnect in Europe. Pools of investment capital are forming around academic science, even as the money needed to get those discoveries into and through the clinic continues to lag. At the scene-setting Bio€quity Europe Face-Off, top Editors Susan Schaeffer of BioCentury and Simone Fishburn of BioCentury Innovations document this conundrum and debate with the audience whether it could thwart European biotech's global ambitions.

With Response from:
Roel Bulthuis, Head, MS Ventures Anne Marden, Portfolio Manager for Global Healthcare Fund, JPMorgan Antoine Papiernik, Managing Partner, Sofinnova
10:30 - 11:00 Coffee Break
11:00 - 12:00

Plenary 1 - Global Venture Scorecard - Hard Facts From U.S. VCs (Room 1)

What's Needed in Europe to Get More U.S. Investor Representation? Over the past several years, Bio€quity Europe has addressed whether European science is competitive on a global landscape and whether European companies have what it takes to play in the Champion's League for capital. This year, we examine both themes from the perspective of U.S. investors. This Bio€quity plenary session brings together U.S. managers who control more than $30 billion in capital to share notes on what is required to get more U.S. investor representation in Europe. And what's needed for them to invest in European biotechs. Plus case studies on successful cross-border investment.

Moderator: Paul Hadden, Managing Director, HealthCare Royalty Partners
Dr. James Healy, General Partner, Sofinnova Ventures
Chau Khuong, Private Equity Partner, OrbiMed
Dr. Ernest Loumaye, Co-Founder and CEO, ObsEva S.A.
Ed Mathers, Partner, NEA
Dr. Kush Parmar, Managing Partner, 5AM Ventures
Kurt von Emster, Managing Partner, Abingworth

Plenary 2 - Old Schools, New Seeds at the Academia - Industry Interface (Room 2)

One year ago, BioCentury's annual review of European biotech finance asked whether innovation is "underfed" in Europe. Today, the "translational" soil is promising a good harvest, with a crop of new seed funds promising to commercialize discoveries from Europe's academic centers. At Bio€quity Europe 2016, architects of these new funds identify what's driving the influx of new money. Has the science become more investable? And what will it take beyond the money to turn these concepts into products for patients?

Moderators: Dr. Tomas Landh, Senior Principal Scientist Innovation Sourcing, Novo Nordisk
John Hallinan, Chief Business Officer, MassBIO
Dr. Laurent Audoly, Managing Partner, Pierre Fabre Fund For Innovation
Dr. Dani Bach, Partner, Imperial Innovations
Dr. Keith Blundy, CEO, Cancer Research Technology
Dr. Johan Kördel, Senior Partner, Lundbeckfond Ventures
Dr. Francesco De Rubertis, Partner, Medicxi Ventures
Graziano Seghezzi, Partner, Sofinnova Partners
12:00 - 14:00 Lunch and Networking Time (Hotel Restaurant)
14:00 - 14:20 Company Presentations

Company Presentations

CEO Boot camp #7
Managing and Hiring for Success - What's the Best CEO Phenotype?

(14:00 - 15:15) (Room 3)

Managing and Hiring for Success. CEOs are responsible not only for company leadership but also for recruiting and hiring key team members. Transitioning from big pharma/biotech or academia to a small biotech can be a challenge. How can the CEO pick those who will succeed in the biotech atmosphere, particularly a start up? How can a CEO ensure their success through the hiring process? The CEO boot camp will evaluate what phenotypes work best for biotech, what strategies have worked and what strategies should be avoided …

Moderator: Carole Nuechterlein, Partner, Roche Venture Fund
Dr. Martin Bonde, CEO, Vaccibody AS
Tim Dyer, CEO, Addex Therapeutics Ltd.
Dr. Christian Elling, Partner, Lundbeckfond Emerge
Elias Papatheodorou, CEO, Genkyotex SA
Next Wave Company Presentations

14:20 - 14:40

14:40 - 15:00
15:00 - 15:20
15:20 - 15:40

Big Pharma / VC Worlds - An Evolving Relationship
(15:30 - 16:45) (Room 3)

Pharma and big biotech are taking new approaches to accessing early stage investments and technology, which have implications for young biotechs. This workshop will explore the dynamic between big pharma and the venture community and explore how young companies can strategically position their growth and interactions with both groups. In addition, it will examine whether corporate VCs have the assets and the ability to fill a void in the private space that has been created by an exodus of crossover investors.

Moderator: Dr. Frank Kalkbrenner, Managing Partner, Boehringer Ingelheim Venture Fund
Dr. Jeanne Bolger, Vice President of Venture Investments, Johnson & Johnson
Dr. Bernard Davitan, Vice President and Managing Director, Sanofi-Genzyme BioVentures
Arthur Franken, Partner, Gilde Healthcare
Dr. Hakan Goker, Senior Investment Director, MS Ventures
Dr. JR Rothe, Managing Partner, LSP
15:40 - 16:00
16:00 - 16:20
16:20 - 16:40
16:40 - 17:00
17:00 - 17:20 Company Presentations
17:20 - 17:40
17:40 - 18:00
18:15 - 18:45 Transportation to Networking Reception and Dinner
19:00 Networking Reception and Dinner
Toldboden - Nordre Toldbod 24
1259 København K

Hosted by The Regional Host Sponsors
2016 Regional Host Sponsors
Wednesday, May 11
07:45 Registration Opens and Light Breakfast (Conference Foyer)
09:00 - 09:20 Company Presentations

Company Presentations

Capital Access - Global vs Local
(09:00-10:00) (Room 3)

Following discussions over the past two years on best practices to access growth capital, this Bio€quity Europe panel discusses listing strategies for biotech companies. What types of companies can cross the pond for a U.S. listing? Are US investors' criteria different from European investors? Are there situations when it is better to list locally with an eye to expand your listing to a U.S. exchange in the future?

Moderator: James Gubbins, Partner, Covington
Dr. Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies
Dr. Florian Fischer, CFO, Affimed N.V.
Alex Ibrahim, Vice President Listings and Capital Markets, NYSE
Dr. Jörg Neermann, Partner, LSP

Next Wave Company Presentations

09:20 - 09:40
09:40 - 10:00
10:00 - 10:20

European Pre-Seed Showcase (10:15-11:15) (Room 3)

Selected Pre-Seed Companies present to a diverse panel of Bio€quity Europe 'judges' who provide high level feedback on their business plan, presentation and overall strategy.

Dr. Karen Bernstein, Chairman & Co-Founder, BioCentury
Kate Bingham, Partner, SV Life Sciences
Dr. Declan Jones, Neuroscience Scientific Innovation, Johnson & Johnson
Dr. Allan Marchington, Senior Advisor, Apposite Capital
Dr. Denise Scots-Knight, CEO, Mereo Biopharma Group Ltd.

Antagonis Biotherapeutics GmbH
AntibioTx ApS
Biopetrolia AB
GlioPharma ApS
NMD Pharma Aps

10:20 - 10:40
10:40 - 11:00
11:00 - 11:20
11:20 - 11:40 Global Ambition - Case Studies
(11:30-12:30) (Room 3)

Against the backdrop of Bio€quity's 'Global Ambitions' theme, this panel asks how VCs should think about creating companies and funding broader ambition. Does the scale of a company's ambition correlate with the scale of the outcome from an investor standpoint?

Dr. Richard Soll, Senior Vice President, International Discovery Service Unit, WuXi AppTec
Dr. Carl-Johan Dalsgaard, CEO, RSPR Pharma AB
Soren Lemonius, Partner, Sunstone
Dr. Genghis Lloyd-Harris, Partner, Abingworth
Dr. Hans Schambye, CEO, Galecto Biotech AB
Dr. Nathalie ter Wengel, European Head Global Scouting External R&D Innovation, Pfizer
11:40 - 12:00
12:00 - 12:20
12:20 - 12:40
12:30 - 14:00 Lunch and Networking Time
14:00 - 14:20 Company Presentations Company Presentations    
14:20 - 14:40
14:40 - 15:00
15:00 - 15:20
15:20 - 15:40
15:40 - 16:00
16:00 Networking Closing Reception